Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
globenewswire.com
business
2022-10-20 20:05:00

Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical trials for 186RNL Initiating ReSPECT-GBM Phase 2 trial for recurrent glioblastoma (GBM) in Q4 2022 Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:Â PSTV) (the 'Company'), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent business highlights.
